The final decision in favor of the treatment was influenced by several key factors: an engaged and mobilized community, including patient associations participating in public consultations and campaigns for drug price reductions; social advocacy for the compulsory licensing of CFTR modulators; the involvement of government officials, even before the evaluation process began, signaling a willingness to engage in dialog; and the active participation of medical professionals through organizations such as the Brazilian Cystic Fibrosis Study Group (GBEFC) and the Brazilian Society of Pulmonology. The gene discussed is CFTR; the disease is cystic fibrosis.